Dian-Sheng Zhong

DNA Damage Response Alterations Stratify Response to ICI-Based Therapy in Advanced NSCLC with High PD-L1 Expression

Patients with multiple DNA damage response gene alterations showed distinct immune profiles, higher rates of durable clinical benefit, and longer progression-free survival, and these findings suggest that genomic DNA damage response alterations may help identify patients who are more likely to benefit from personalized...